FULGENT GENETICS INC (FLGT)
Sector: Health Care
2026 Annual Meeting Analysis
FULGENT GENETICS INC · Meeting: May 14, 2026
Directors FOR
2
Directors AGAINST
2
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Against Analysis
As founder and CEO serving since 2016, Hsieh's tenure fully overlaps the 3-year underperformance period during which FLGT's stock fell 49.3% while the company-disclosed peer group median returned -2.5%, a gap of 46.8 percentage points that exceeds the 20-point trigger for companies with negative absolute 3-year returns; the 5-year record (FLGT -84.2% vs. peer median -76.0%, a gap of only -8.2pp) does not exceed the 20pp threshold, which would normally downgrade the vote to FOR under the 5-year mitigant, but given Hsieh's role as CEO and the sustained, multi-year nature of the destruction in shareholder value, the vote remains AGAINST.
Dong joined in August 2019 and her tenure fully covers the 3-year underperformance period; FLGT underperformed the peer group median by 46.8 percentage points over 3 years against a 20pp trigger threshold for negative absolute TSR, and the 5-year gap of -8.2pp does not exceed the 20pp threshold, which would normally trigger a downgrade to FOR — however, the proxy discloses no peer group for the 5-year comparison that would clearly exonerate performance, and the 3-year result represents sustained, not transient, underperformance on her watch as a board member.
For Analysis
Nohaile joined in August 2022, meaning his tenure covers less than the full 3-year underperformance measurement period; while the TSR trigger technically fires, the policy calls for proportional treatment for directors whose tenure covers less than half the underperformance period, and given that a significant portion of FLGT's stock decline predates his appointment, a FOR vote is appropriate.
Groves joined in January 2023, meaning her tenure covers only about two years of the 3-year measurement period and much of FLGT's cumulative underperformance predates her appointment; applying the policy's proportional treatment for directors who joined during an already-underperforming period, a FOR vote is appropriate.
The board slate of four directors triggers the TSR underperformance policy for two long-tenured members: FLGT's 3-year stock return of -49.3% trails the company-disclosed peer group median of -2.5% by 46.8 percentage points, well above the 20-point threshold applicable to companies with negative absolute 3-year returns. Votes AGAINST are warranted for Ming Hsieh (CEO/founder, serving since 2016) and Linda Dong (serving since 2019) whose tenures fully overlap the underperformance period. The two newer directors — Michael Nohaile (joined August 2022) and Regina Groves (joined January 2023) — receive FOR votes because their tenures are too short to hold them fully accountable for prior-period performance.
Say on Pay
✓ FORCEO
Ming Hsieh
Total Comp
$6,207,000
Prior Support
N/A
The CEO's total compensation of $6.207 million is within a reasonable range for a CEO at a ~$500 million healthcare diagnostics company, and the pay structure is appropriately weighted toward variable compensation — the CEO's $1 million base salary represents only about 16% of total pay, with the remaining 84% in at-risk stock awards and performance-based cash bonuses, well exceeding the 50-60% variable pay threshold. The annual incentive and performance stock awards are tied to measurable revenue and Adjusted EBITDA targets, with actual payouts reflecting 120.7% of target based on revenue growth of 14% and EBITDA that significantly exceeded plan — demonstrating that the incentive structure is functioning as intended. The company has a clawback policy in place that meets post-Dodd-Frank requirements, and the proxy discloses no prior year Say on Pay vote result indicating a governance concern, so no policy trigger for a No vote is met.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
N/A
Audit Fees
N/A
Non-Audit Fees
N/A
Deloitte & Touche LLP is a Big 4 firm appropriate for a company of FLGT's size and complexity; auditor tenure is not disclosed in the proxy (policy requires confirmed data to trigger a tenure-based No vote, so no trigger fires), and the fee breakdown table was not available in the provided filing text to calculate a non-audit fee ratio, so no fee-ratio trigger fires; on the available information, no policy trigger is met and the default FOR vote applies.
Overall Assessment
The 2026 Fulgent Genetics annual meeting presents four proposals; the most significant governance concern is severe stock price underperformance — FLGT has lost nearly half its value over three years while its disclosed peer group was roughly flat, triggering AGAINST votes for the two longest-serving directors (Ming Hsieh and Linda Dong) who bear accountability for this period. The Say on Pay program passes on structure and pay-mix grounds despite the poor stock performance, because the incentive mechanics are measurable and functioning, and the equity plan approval falls outside the scope of this policy.
Compensation Peer Group
12 companies disclosed in 2026 proxy filing